Notably, IL‐33 has been targeted in several clinical trials for conditions such as asthma, chronic obstructive pulmonary disease, and atopic dermatitis, which offers potential therapeutic strategies for targeting IL‐33 in the context of pathological new bone formation. This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.